home.social

#versanis — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #versanis, aggregated by home.social.

  1. Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

    Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

    #Wegovy #Mounjaro #ozempic #weightloss
    bioprocessintl.com/bioprocess-

  2. Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

    Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

    #Wegovy #Mounjaro #ozempic #weightloss
    bioprocessintl.com/bioprocess-

  3. Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

    Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

    #Wegovy #Mounjaro #ozempic #weightloss
    bioprocessintl.com/bioprocess-

  4. Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

    Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

    #Wegovy #Mounjaro #ozempic #weightloss
    bioprocessintl.com/bioprocess-

  5. Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

    Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

    #Wegovy #Mounjaro #ozempic #weightloss
    bioprocessintl.com/bioprocess-